Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson’s latest earnings bested Wall Street estimates, as the company braces for one of its top-selling medicines to go off patent in the coming weeks.
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone treatment for adults with major depressive disorder who failed at least two oral antidepressants. Previously, it was only approved with oral antidepressants for treatment-resistant depression.
J&J Beats Quarterly Sales and Profit Estimates on Cancer Drug Sales
Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments.
Johnson & Johnson: Q4 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2 per share. The world's biggest maker of health care products posted revenue of $22.52 billion in the period,
Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness
Johnson & Johnson (NYSE:JNJ) traded flat in the premarket on Wednesday after the pharma giant exceeded Street forecasts for Q4 2024, mainly due to its Innovative Medicine unit, while its MedTech division fell short of expectations.
17h
on MSN
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
18h
Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'?
Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the ...
23h
Johnson & Johnson (JNJ) Receives a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...
1d
Ben Johnson to Chicago Bears is a gut punch because he knows the Detroit Lions' recipe
Chicago has hired Detroit Lions OC Ben Johnson to be their next head coach. The toughest division in the NFL could get even ...
TipRanks on MSN
2d
Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards
Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single ...
10h
on MSN
Jim Cramer on Johnson & Johnson (JNJ): ‘Make Good Money Just By Reinvesting Their Juicy Dividends’
We recently published an article titled Jim Cramer Discussed 9 Stocks for This Week’s Game Plan. In this article, we are ...
16h
on MSN
Dakota Johnson and Chris Martin Hold Hands While on Walk Together in Mumbai
Dakota Johnson and Chris Martin were photographed holding hands as they went for a walk in Mumbai on Tuesday, Jan. 21. Martin ...
13h
Credit Bears brass for winning Ben Johnson's recruiting battle
It was easy to roll your eyes two weeks ago Wednesday when Warren painted the Bears’ head coaching job as the best available ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Trump
New York
NFL
Chicago Bears
California
Feedback